Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$6.66
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.66
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$3.92 - $15.40
Previous CloseN/A
Volume477.34K
Average Volume (3M)4.13M
Market Cap
$1.67B
Enterprise Value$307.29
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume6,044,957
30 Day Avg. Volume4,129,312
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.43Price Target Upside266.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$2.31M
Bulls Say, Bears Say
Bulls Say
Robust Phase III Clinical DatasetLarge, late‑stage clinical evidence with unprecedented 26‑week blinded durability across two pivotal trials strengthens the program's regulatory credibility and commercial proposition. A robust efficacy/durability profile supports labeling, payer dossiers, and clinician adoption over the medium term.
Rolling NDA And Priority VoucherA rolling NDA pathway plus a CNPV materially shortens potential review timelines and concentrates regulatory risk into clear milestones. This structural regulatory advantage can accelerate market access and reduce execution uncertainty vs. peers without similar acceleration mechanisms.
Commercial Readiness And Cash RunwayInvesting in experienced commercial leadership and expanding field infrastructure while reporting runway to 2028 provides durable capacity to execute a launch. This alignment of commercial buildout and funding reduces immediate execution risk around sales force, site engagement and REMS preparation.
Bears Say
Persistent Cash Burn And LossesSustained negative operating and free cash flow indicates the business depends on external funding until commercial revenues scale. Ongoing cash burn raises dilution and refinancing risk if launch timing slips or reimbursement is delayed, pressuring long‑term capital structure and strategy.
Balance‑sheet Volatility And Past Negative EquityHistoric negative equity and subsequent swings point to reliance on episodic financings and valuation volatility. Such balance‑sheet instability can dilute shareholders, compress returns and complicate long‑term planning for commercialization and M&A strategies.
Reimbursement And Valuation Work Needed For CPT CodesCategory III billing codes limit durable reimbursement certainty until Category I status and RVU valuation are achieved through committee processes. This structural reimbursement risk can delay predictable cash flows, complicate payer negotiations, and constrain adoption even after regulatory approval.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $3.92 and its highest was $15.40 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $1.67B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of -$0.439 by $1.149.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.39.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $0.71 in its last earnings report, beating expectations of -$0.439. Following the earnings report the stock price went up 16.969%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.43 (266.80% Upside)
$24.43 (266.80% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
CMPS Stock 12 Month Forecast
Average Price Target
$24.43
▲(266.80% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.41% Insiders
1.29% Mutual Funds
0.53% Other Institutional Investors
93.00% Public Companies and Individual Investors